China Resources Pharmaceutical Group (HKG:3320) subsidiary China Resources Boya Bio-pharmaceutical Group (SHE:300294) expects to record net profit attributable to the shareholders between 380.00 million yuan and 480.00 million yuan in 2024, higher than 237.5 million yuan logged for the preceding year, a Wednesday Hong Kong bourse filing said.
China Resources Boya Bio-pharmaceutical Group attributed the increase in expected profit to a rise in revenue from its blood products and the impact of non-recurring gains and losses on its net profit during the reporting period.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。